Leonteq Securities AG Invests $1.16 Million in CRISPR Therapeutics AG $CRSP

Leonteq Securities AG acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 22,020 shares of the company’s stock, valued at approximately $1,155,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. IFP Advisors Inc raised its stake in shares of CRISPR Therapeutics by 29.9% during the 4th quarter. IFP Advisors Inc now owns 1,250 shares of the company’s stock worth $66,000 after purchasing an additional 288 shares in the last quarter. PSP Research LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $502,000. Quantum Private Wealth LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $257,000. PNC Financial Services Group Inc. increased its holdings in shares of CRISPR Therapeutics by 16.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,713 shares of the company’s stock worth $404,000 after acquiring an additional 1,082 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 263.0% during the 4th quarter. Larson Financial Group LLC now owns 882 shares of the company’s stock worth $46,000 after acquiring an additional 639 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $49.90 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. The stock’s fifty day moving average price is $50.87 and its two-hundred day moving average price is $53.28. CRISPR Therapeutics AG has a one year low of $35.38 and a one year high of $78.48. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of -8.02 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.08 EPS for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares in the company, valued at $11,952,336.78. This represents a 3.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel James R. Kasinger sold 3,182 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the sale, the general counsel owned 94,308 shares of the company’s stock, valued at approximately $4,411,728.24. This represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 42,749 shares of company stock worth $2,100,723 in the last ninety days. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CRSP. TD Cowen boosted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Sanford C. Bernstein boosted their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Evercore reissued an “outperform” rating and set a $76.00 target price on shares of CRISPR Therapeutics in a report on Monday, May 11th. Bank of America decreased their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Finally, Morgan Stanley reissued an “underweight” rating and set a $33.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $65.47.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.